In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations

Journal of Infection and Chemotherapy

Volumn 21, Issue 2, 2015, Pages 148-151

  Yoshizumi, Ayumi ^a   Ishii, Yoshikazu ^a   Aoki, Kotaro ^a   Testa, Raymond ^b   Nichols, Wright W ^b   Tateda, Kazuhiro ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antibiotic resistance; Avibactam; Aztreonam avibactam; Ceftaroline avibactam; Ceftazidime avibactam

Indexed keywords

AVIBACTAM; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CEFTAROLINE; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DRUG EFFECTS; ENZYMOLOGY; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS;

EID: 84928412328     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.08.028     Document Type: Article

References (20)

1. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., et al. Activities of NXL 104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011, 55:390-394.
2. Mushtaq S., Warner M., Livermore D.M. Invitro activity of ceftazidime+NXL 104 against Pseudomonas aeruginosa and other non-fermenters. JAntimicrob Chemother 2010, 65:2376-2381.
3. Castanheira M., Farrell S.E., Krause K.M., Jones R.N., Sader H.S. Contemporary diversity of β-lactamases among Enterobacteriaceae in nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014, 58:833-838.
4. Endimiani A., Choudhary Y., Bonomo R.A. Invitro activity of NXL104 in combination with beta-lactamase against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009, 53:3599-3601.
5. Poirel L., Naas T., Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 2010, 54:24-28.
6. Rapp R.P., Urban C. Klebsiella pneumonia carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacother 2012, 32:399-407.
7. Bonnefoy A., Dupuis-Hamelin C., Steier V., Delachaume C., Seys C., Stachyra T., et al. Invitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. JAntimicrob Chemother 2004, 54:410-417.
8. Lahiri S.D., Mangani S., Durand-Reville T., Benvenuti M., De Luca F., Sanyal G., et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 2013, 57:2496-2505.
9. Sader H.S., Castanheira M., Flamm R.K., Farrell D.J., Jones R.N. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 2014, 58:1684-1692.
10. Wang X., Zhang F., Zhao C., Wang Z., Nichols W.W., Testa R., et al. Invitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014, 58:1774-1778.
11. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 2012, Approved Standard-9th Edition, M07-A09, CLSI, Wayne, PA, USA.
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement M100-S23 2013, CLSI, Wayne, PA, USA.
13. Livermore D.M., Mushtaq S., Warner M., Miossec C., Woodford N. NXL 104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. JAntimicrob Chemother 2008, 62:1053-1056.
14. Lagacé-Wiens P.R.C., Tailor F., Simner P., DeCorby M., Karlowsky J.A., Walky A., et al. Activity of NXL104 in combination with β-lactams against genetically characterized class A ESBL and Class C β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:2434-2437.
15. Heritier C., Poirel L., Lambert T., Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005, 49:3198-3202.
16. Dhillon R.H.P., Clark J. ESBLs: a clear and present danger?. Crit Care Res Pract 2012, ID 625170. 10.1155/2012/625170.
17. Biehl L.M., Schmidt-Hieber M., Liss B., Cornely O.A., Vehreschild M.J.G.T. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - review of the literature from a clinical perspective. Crit Rev Microbiol 2014, [Epub ahead of print].
18. Bush K. Carbapenemases: partners in crime. JGlob Antimicrob Resist 2013, 1:7-16.
19. Ishii Y., Ichikawa M., Yamaguchi K., Takano K., Inoue M. Localization of cephalosporinase in Enterobacter cloacae by immunocytochemical examination. JAntibiot (Tokyo) 1991, 44:1088-1095.
20. Marshall M.J., Ross G.W., Chanter K.V., Harris A.M. Comparison of the substrate specificities of the -lactamases from Klebsiella aerogenes 1082E and Enterobacter cloacae P99. Appl Microbiol 1972, 23:765-769.